Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Debt Repayments (2016 - 2018)

Gyre Therapeutics (GYRE) has disclosed Long-Term Debt Repayments for 9 consecutive years, with $5.1 million as the latest value for Q1 2018.

  • Quarterly Long-Term Debt Repayments fell 24.73% to $5.1 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2018, down 64.51% year-over-year, with the annual reading at $5.1 million for FY2018, 64.51% down from the prior year.
  • Long-Term Debt Repayments for Q1 2018 was $5.1 million at Gyre Therapeutics, up from $403000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $10.3 million in Q4 2016, with the low at $218000.0 in Q1 2014.
  • Average Long-Term Debt Repayments over 5 years is $2.7 million, with a median of $676000.0 recorded in 2016.
  • The sharpest move saw Long-Term Debt Repayments soared 1089.46% in 2016, then crashed 96.07% in 2017.
  • Over 5 years, Long-Term Debt Repayments stood at $500000.0 in 2014, then skyrocketed by 72.6% to $863000.0 in 2015, then skyrocketed by 1089.46% to $10.3 million in 2016, then plummeted by 96.07% to $403000.0 in 2017, then skyrocketed by 1161.04% to $5.1 million in 2018.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $5.1 million, $403000.0, and $282000.0 for Q1 2018, Q4 2017, and Q3 2017 respectively.